摘要
目的观察益气化痰汤辅助治疗老年晚期肺癌的临床疗效及安全性。方法将81例老年晚期肺癌患者随机分为对照组40例与试验组41例。对照组予以第1天静脉滴注75 g·m^(-2)紫杉醇注射液+第1天静脉滴注60 mg·m^(-2)顺铂+口服吉非替尼250 mg,qd;试验组在对照组治疗的基础上,予以口服益气化痰汤,每天1剂。2组患者一个周期均为7 d,共治疗4个周期。比较2组患者的临床疗效、血清癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)、神经特异性烯醇化酶(NSE)、血管内皮生长因子(VEGF)、细胞外信号调节激酶(ERK)水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的疾病控制率分别为90.24%(37/41例)和72.50%(29/40例),差异有统计学意义(P<0.05)。治疗后,试验组与对照组的CEA分别为(92.74±10.57),(120.45±13.96)ng·mL^(-1);CYFRA21^(-1)分别为(92.74±10.57),(114.54±11.74)ng·mL^(-1);NSE分别为(7.04±0.81),(8.45±0.94)ng·mL^(-1);ERK分别为(0.97±0.11),(1.49±0.16)μg·mL^(-1);VEGF分别为(5.80±0.63),(17.74±1.92)ng·mL^(-1),差异均有统计学意义(均P<0.05)。试验组的0.5,1,2年生存率分别为97.56%,95.12%,90.24%,对照组的0.5,1,2年生存率分别为92.50%,87.50%,72.50%,差异均有统计学意义(均P<0.05)。2组患者的药物不良反应以胸痛、呕吐合并食欲缺乏、发热为主,试验组和对照组的药物不良反应发生率分别为7.32%和17.50%,差异有统计学意义(P<0.05)。结论益气化痰汤辅助治疗老年晚期肺癌的临床疗效显著,且安全性较高。
Objective To observe the clinical efficacy and safety of Yiqi Huatan decoction in the treatment of elderly advanced lung cancer. Methods Eighty -one elderly patients with advanced lung cancer were randomly divided into control group （n = 40 cases） and treatment group （n =41 cases）. Control group was given 75 g·m^-2 paclitaxel intrave- nous infusion on day 1 ± 60 mg·m^-2 cisplatin intravenous infusion on day 1 ± gefitinib 250 mg oral qd. Treatment group was treated with Yiqi Huatan decoction once daily, on the basis of control group. Two groups were treated for 4 cycles with 7 d per cycle. The clinical efficacy, serum levels of cancer embryonic antigen （CEA）, cytokeratin fragment 19 （ CYFRA21 - 1 ）, neuron specific enolase （ NSE ）, vascular endothelial growth factor （VEGF）, extracellular signal regulated kinase （ERK） and the incidence of adverse drug reactions were compared between two groups. Results After treatment, the disease control rates in treatment and control groups were 90. 24% （37/41 cases） and 72. 50% （29/40 cases）, with significant difference （P 〈 0. 05 ）. After treatment, the levels of CEA in treatment and control groups were （92.74 ± 10.57）, （120.45± 13.96） ng·mL^-1; CYFRA21 - 1 were （92.74 ± 10.57）, （114.54±11.74）ng·mL^-1; NSE were （7.04 ±0.81）, （8.45 ±0.94）ng·mL^-1; ERK were （0.97 ±0.11）, （ 1.49 ±0. 16） I-g·mL^-1; VEGF were （ 5. 80 ± 0. 63 ）, （ 17. 74 ± 1.92 ） ng·mL^-1, with significant differences （P 〈0. 05）, The survival rates of 0. 5, 1 and 2 years in treatment group were 97.56%, 95.12%, 90.24% ; the survival rates of 0. 5, 1 and 2 years in the control group were 92. 50% ,87. 50% ,72. 50%, with significant difference （P 〈0. 05）. Adverse drug reactions were focused on chest pain, loss of appetite and vomiting, and fever in two groups, and the incidence of adverse drug reactions in treatment and control groups were 7. 32% and 17. 50%, with significant difference （P 〈 0. 05 ）. Con
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2017年第10期873-876,共4页
The Chinese Journal of Clinical Pharmacology
基金
河南省医学科技攻关计划基金资助项目(B112102310102)
关键词
紫杉醇注射液
顺铂注射液
吉非替尼片
益气化痰汤
老年晚期肺癌
paclitaxel injection
cisplatin injection
gefitinib
Yiqi Huatan decoction
elderly advanced lung cancer
